COGT

Cogent Biosciences is a drug development company working on treatments for rare genetic diseases and certain cancers. Their main drug candidate, bezuclastinib, is designed to treat systemic mastocytosis and a type of stomach cancer called gastrointestinal stromal tumors by targeting specific genetic mutations that drive these diseases. The company is also developing several other experimental drugs targeting different genetic mutations found in various cancers. They are currently testing these drugs in clinical trials with patients.